BioSpace News Archive

Business

Allergan to Slash 1,000+ Jobs

Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.

January 3, 2018
·
2 min read
·
Alex Keown
Business

NYC Startup Syntimmune Names Former Biogen Exec as New CEO

Syntimmune has appointed Jean-Paul Kress as president and CEO.

January 3, 2018
·
2 min read
·
Mark Terry
Biotech Bay

Spark’s Blindness-Curing Gene Therapy Comes With a $850,000 Price Tag

The therapy is the first type approved by the FDA that targets a disease caused by mutations in a specific gene.

January 3, 2018
·
3 min read
·
Alex Keown
Business

Neogen Corp. Reports Record Revenues and Earnings

Neogen announced today that its revenues for the second quarter of its 2018 fiscal year, which ended Nov. 30, increased 12% to $101,817,000, from the previous year’s second quarter revenues of $90,717,000.

January 3, 2018
·
7 min read
Business

Ex-aTyr Pharma CEO Takes Gig at Mysterious Moderna

Dr. Mendlein will be responsible for corporate strategy, product advancement and strategy, partnering and product protection.

January 3, 2018
·
4 min read
Seegene Develops World’s First Multiplex MDx Assays With its AI System

Seegene announced today that, utilizing a newly created AI based assay development system, the company succeeded in developing MDx assays in only four days.

January 3, 2018
·
2 min read
Biotech Beach

OncoSec Provides 2018 Business Outlook

OncoSec Medical announced its anticipated operational milestones for 2018 and a review of business highlights for year-end 2017.

January 3, 2018
·
12 min read
Business

Taiho Oncology Names Timothy Whitten President

Taiho Oncology today announced the promotion of Timothy Whitten from Senior VP and COO to President, effective January 1, 2018.

January 3, 2018
·
6 min read
Pharm Country

Janssen Release: Landmark Schizophrenia Data That Bring Hope in Breaking the Cycle of Hospitalization and Incarceration Receive FDA Approval for Inclusion in INVEGA SUSTENNA (paliperidone palmitate) Label

Janssen today announced INVEGA SUSTENNA, a once-monthly schizophrenia treatment, is the first and only antipsychotic to have the FDA approve the inclusion of real-world data in its product labeling.

January 3, 2018
·
14 min read
Policy

Perrigo Announces Tentative FDA Approval for the Generic Version of Prolensa Ophthalmic Solution 0.07%

Perrigo previously settled litigation with Bausch & Lomb for this product.

January 3, 2018
·
4 min read